Primary Hypertension To Predict Progression-Free Survival Of Target Therapy In Patients With Metastatic Renal Cell Carcinoma

e15052 Background: Primary Hypertension(PH) was identified as a risk factor for RCC(renal cell carcinoma) in previous studies, only one report showed history of hypertension predicted better survival in RCC patients. In recent years, treatment related hypertension (TRH) was found to be associated with clinical outcome of targeted therapy. However, little is known about whether primary hypertension had an effect on survival of mRCC patients treated with targeted therapy. The objective of this study was to investigate the effects of primary hypertension on treatment outcome in patients treated with targeted therapy for metastatic RCC (mRCC). Methods: We conducted follow-up on a cohort of consecutiave mRCC cases treated with sunitinib or sorafenib in our center. Baseline characters were recorded such as age, gender, blood pressure, stage, et al. All the patients were followed up for progression free survival (PFS), overall survival (OS), objective response rate(RR). Results: We studied a cohort of 77 cases, ...